Evidence map›Paper›PMID 29484572›Full record

Observational studyDigestive diseases and sciences2018

Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.

Sunil Taneja, Ajay Duseja, Arka De, Manu Mehta, Raja Ramachandran, Vivek Kumar, Harbir Singh Kohli, Krishan Lal Gupta, Radha Krishan Dhiman, Yogesh Chawla

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 4 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 4 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Hepatitis C virus infection and chronic renal disease: A review.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2018
    Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sunil TanejaDepartment of Hepatology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, 160012, India.
Ajay DusejaDepartment of Hepatology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, 160012, India. ajayduseja@yahoo.co.in.
Arka DeDepartment of Hepatology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, 160012, India.
Manu MehtaDepartment of Hepatology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, 160012, India.
Raja RamachandranDepartment of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Vivek KumarDepartment of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Harbir Singh KohliDepartment of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Krishan Lal GuptaDepartment of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Radha Krishan DhimanDepartment of Hepatology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, 160012, India.
Yogesh ChawlaDepartment of Hepatology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, 160012, India.
Post Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsThere is sparse data on the use of Sofosbuvir based directly acting antiviral (DAA) drug regimens in chronic hepatitis C (CHC) patients with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m

methodsSixty-five CHC patients with CKD with eGFR less than 30 mL/min/1.73 m

resultsThe median HCV RNA level in 65 patients (Males 40, mean age 42.9 ± 13 years) was 1.65 × 10

conclusionLow-dose Sofosbuvir and full-dose Daclatasvir are safe and effective in treating CHC in patients with CKD with eGFR less than 30 mL/min/1.73 m

Indexed as

AdultAntiviral AgentsCarbamatesDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesGlomerular Filtration RateHepatitis C, ChronicHumansImidazolesKidney Failure, ChronicMaleMiddle AgedProspective StudiesPyrrolidinesAntiviral AgentsCarbamatesdaclatasvirImidazolesPyrrolidinesSofosbuvirValineChronic hepatitis CChronic kidney diseaseDaclatasvirSofosbuvir

Identifiers

PMID29484572
OpenAlexW2793357379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.